Hit the target - IL-6 in rare neuroimmunological conditions
Join Our Expert:
Prof Anthony Traboulsee
Speaker
MS Society of Canada at the University of British Columbia
Vancouver, Canada
Thursday, October 22
Industry Theatre
1:35 - 1:55 PM
The IL-6 signaling pathway is well recognised as a central driver in rare CNS autoimmune conditions and has opened a new therapeutic chapter. This meeting will explore the multifaceted role of IL-6—a pleiotropic cytokine that not only fuels inflammation but also compromises the blood-brain barrier and promotes the survival of pathogenic plasmablasts through upstream mechanisms. As we look toward the future of rare disease management, we will evaluate the clinical value of IL-6 inhibition across a spectrum of disorders, including NMOSD, MOGAD, and Autoimmune Encephalitis.
The clinical expert will discuss how targeting this specific "cytokine hub" can reduce relapse risk, manage long-term disability with an acceptable long-term safety and tolerability profile and convenient administration.
CNS, Central Nervous System; IL-6, Interleukin-6; MOGAD, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease; NMOSD, Neuromyelitis Optica Spectrum Disorder